Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2003 1
2004 5
2005 8
2006 9
2007 9
2008 17
2009 19
2010 25
2011 32
2012 20
2013 28
2014 21
2015 15
2016 11
2017 15
2018 11
2019 17
2020 27
2021 30
2022 23
2023 16
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

322 results

Results by year

Filters applied: . Clear all
Page 1
Nanomedicines: The magic bullets reaching their target?
Flühmann B, Ntai I, Borchard G, Simoens S, Mühlebach S. Flühmann B, et al. Among authors: simoens s. Eur J Pharm Sci. 2019 Feb 1;128:73-80. doi: 10.1016/j.ejps.2018.11.019. Epub 2018 Nov 20. Eur J Pharm Sci. 2019. PMID: 30465818 Free article. Review.
The necessity for a European definition of drug shortages.
De Weerdt E, Simoens S, Casteels M, Huys I. De Weerdt E, et al. Among authors: simoens s. Int J Pharm Pract. 2018 Aug;26(4):289-290. doi: 10.1111/ijpp.12459. Int J Pharm Pract. 2018. PMID: 29972611 No abstract available.
Learnings from cross-border biosimilar pricing policies in Europe.
Simoens S, Lacosta TB, Inotai A. Simoens S, et al. Expert Rev Pharmacoecon Outcomes Res. 2024 Mar 26:1-4. doi: 10.1080/14737167.2024.2334343. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38530083 No abstract available.
Tendering and biosimilars: what role for value-added services?
Simoens S, Cheung R. Simoens S, et al. J Mark Access Health Policy. 2019 Dec 22;8(1):1705120. doi: 10.1080/20016689.2019.1705120. eCollection 2020. J Mark Access Health Policy. 2019. PMID: 32002174 Free PMC article. Review.
Pharmaco-economic aspects of sipuleucel-T.
Simoens S. Simoens S. Hum Vaccin Immunother. 2012 Apr;8(4):506-8. doi: 10.4161/hv.18334. Epub 2012 Feb 16. Hum Vaccin Immunother. 2012. PMID: 22336882 Review.
R&D Costs of New Medicines: A Landscape Analysis.
Simoens S, Huys I. Simoens S, et al. Front Med (Lausanne). 2021 Oct 26;8:760762. doi: 10.3389/fmed.2021.760762. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34765624 Free PMC article. Review.
Integrative Review of Managed Entry Agreements: Chances and Limitations.
Zampirolli Dias C, Godman B, Gargano LP, Azevedo PS, Garcia MM, Souza Cazarim M, Pantuzza LLN, Ribeiro-Junior NG, Pereira AL, Borin MC, de Figueiredo Zuppo I, Iunes R, Pippo T, Hauegen RC, Vassalo C, Laba TL, Simoens S, Márquez S, Gomez C, Voncina L, Selke GW, Garattini L, Kwon HY, Gulbinovic J, Lipinska A, Pomorski M, McClure L, Fürst J, Gambogi R, Ortiz CH, Canuto Santos VC, Araújo DV, Araujo VE, Acurcio FA, Alvares-Teodoro J, Guerra-Junior AA. Zampirolli Dias C, et al. Among authors: simoens s. Pharmacoeconomics. 2020 Nov;38(11):1165-1185. doi: 10.1007/s40273-020-00943-1. Pharmacoeconomics. 2020. PMID: 32734573 Free article. Review.
Hurdles that impede economic evaluations of welfare interventions.
Schepers J, Annemans L, Simoens S. Schepers J, et al. Among authors: simoens s. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):635-42. doi: 10.1586/14737167.2015.1045492. Epub 2015 May 11. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25961757 Review.
322 results